Analyzing the effect of serum uric acid reduction using Allopurinol on vitamin D levels in hemodialysis patients

Analyzing the effect of serum uric acid reduction using Allopurinol on vitamin D (25OHD) levels in hemodialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015041721803N1

Enrollment

Registered

2017-05-28

Start date

2017-02-18

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis patients. Extracorporeal dialysis

Interventions

Intervention 1: Allopurinol tablet, 100 mg, daily for 60 days. Intervention 2: Placebo tablet, daily for 60 days.

Treatment - Drugs

Placebo

Allopurinol tablet, 100 mg, daily for 60 days

Placebo tablet, daily for 60 days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Hemodialysis patients; ESRD; Asymptomatic hyperuricemia; Exclusion criteria: Taking Uric acid reducting agents; Taking vitamin D supplements;

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Vitamin D level. Timepoint: Before and after hyperuricemia treatment. Method of measurement: 25OHD serum level immunoassey.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNegar Karevan

Shahrekord University of Medical Sciences

st_Karevan.N@skums.ac.ir+98 38132220016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 10, 2026